Skip to main content
. 2003 Nov 28;2:16. doi: 10.1186/1475-2840-2-16

Figure 1.

Figure 1

Effect of six month therapy with trimetazidine or placebo on top of usual medical care in patients with type 2 diabetes. Trimetazidine significantly reduced left ventricular end diastolic (LVEDD) and end systolic (LVESD) diameters compared to both baseline examination and placebo. TMZ = Trimetazidine, PBO = Placebo